Abstract
Treatment options for osteoporosis are limited for older individuals with chronic kidney disease. A secondary analysis of the FREEDOM trial sheds light on the efficacy and safety of denosumab in patients with impaired kidney function, but underlines that challenges remain in the treatment of osteoporosis in patients with severe chronic kidney disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
